Methylation Biomarkers for Diagnosis of Prostate Cancer
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Apr 2, 2012
filing date -
Apr 4, 2011
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Biomarkers for diagnosis and prognosis of prostate cancer are provided. The biomarkers are promoter sequences have altered methylation patterns relative to normal prostate tissue. Altered expression of DNA methyltransferases (DNMT) and proteins that interact with DNMT result in increased methylation at a subset of prostate tumor hypermethylation sites.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully